undruggable targets

Antares and Rho Ophiuchi cloud complex in the Sagittarius constellation
Biotech

Novartis pays Antares $105M to tackle undruggable cancer targets

Novartis is paying Antares $105 million upfront in a deal worth up to $1.9 billion to tackle historically undruggable cancer targets.
Nick Paul Taylor Jun 24, 2026 9:13am
Alphabet letters spelling

Terremoto takes $108M series C to fuel trials of AKT1 inhibitors

Apr 15, 2026 7:43am
Two businessmen pushing giant puzzle pieces together as the sun sets behind them

Novartis finds natural partnership in macrocycle biotech

Feb 18, 2026 10:13am
business targets illustration

Argenx's $1.5B pact to turn macrocyclic peptides to new targets

Jul 1, 2025 8:00am
IPO

GPCR firm Septerna files for IPO on strength of preclinical data

Oct 3, 2024 6:00am
An artists illustration of a KRAS G12C mutation in non-small cell lung cancer

AACR: KRAS inhibitors pop in preclinical data debuts

Apr 11, 2024 4:30am